Molecules 2019, 24, 2084
8 of 10
1
4-Bromo-2,6-bis(4-chlorophenyl)-tetrahydro-2H-pyran (6b): H NMR (500 MHz, CDCl3)
δ
= 7.34 (m, 8H,
ArH), 4.54 (dd, J = 10.0, 2H, 8.0, H2ax e H6ax), 4.42 (m, 1H, H4ax), 2.54 (m, 1H, H3ax e H5ax), 2.06 (m,
1H, H3eq e H5eq); 13C NMR (125 MHz, CDCl3)
Yield 73%.
δ = 139.47, 133.59, 128.66, 127.14, 79.06, 45.27, 44.81.
4-Bromo-tetrahydro-2,6-dip-tolyl-2H-pyran (7b): 1H NMR (500 MHz, CDCl3)
δ = 7.31 (m, 8H, ArH),
4.54 (dd, J = 10.0 Hz, 2H, H2ax e H6ax), 4.45 (m, 1H, H4ax), 2.55 (m, 1H, H3ax e H5ax), 2,36 (s, 6H), 2.12
(m, 3H, H3eq e H5eq); 13C NMR (125 MHz, CDCl3)
16,25. Yield 60%.
δ
= 133.48, 132.51, 124.16, 120.99, 74.73, 41.55, 40.23,
1
4-Bromo-tetrahydro-2,6-bis(4-nitrophenyl)-2H-pyran (8b): H NMR (500 MHz, CDCl3)
δ
= 8.28 (m, 4H,
ArH), 7.63 (m, 4H, ArH), 4.75 (dd, J = 10.0, 2H, H2ax e H6ax), 4.49 (m, 1H, H4ax), 2.66 (m, 2H, H3ax
e
H5ax), 2.12 (m, 2H, H3eq e H5eq); 13C NMR (125 MHz, CDCl3)
43.87. Yield 40%.
δ = 147.55, 126.39, 123.84, 78.69, 44.32,
1
4-Bromo-tetrahidro-2,6-dihexyltetrahidropyrano (9b): H NMR (500 MHz, CDCl3):
δ = 4.12 (m, H4ax),
3.21 (m, H2ax e H6ax), 2.17 (dd, J = 10.0 Hz, H3eq e H5eq), 1.61 (m, H3ax e H5ax), 1.24 (m, 24H, (CH2)6),
0.83 (t, 6H, CH3). 13C NMR (125 MHz, CDCl3):
13.94. Yield 60%.
δ = 77.52, 47.33, 43.43, 35.74, 31.65, 29.03, 25.34, 22.45,
4. Conclusions
In this study, we showed tandem reactions combining Barbier and Prins for produces
stetrahydropyrans compounds from an allylbromide, tin halide, and aldehyde, promoted by the
ionic liquid [BMIM][PF6] with moderate to good yields in just an 8 h reaction. With other parallel
-
experiments, we can see how the reagents work in two reactions. In addition, the PF6 anion presents
in ionic liquid besides contributing the ionic medium to the reaction mechanism acts to accelerate the
reaction and only ionic medium influence on the Prins cyclization. Slight excess of SnBr2 under the
reaction conditions of the Barbier reaction leads to the formation of the product of THPs, thus acting as
a catalyst for Prins cyclization.
Author Contributions: The authors P.K.B., J.M.G.d.O.F. and F.P.L.S. were responsible for Investigation,
methodology, validation, formal analysis and Writing-Original Draft Preparation. The author M.L.A.A V. was
responsible for Investigation, Writing-Original Draft Preparation and Funding Acquisition. The corresponding
author J.A.V. was responsible for Conceptualization, Resources, Writing-Original Draft Preparation, Writing-Review
& Editing and Supervision.
Funding: This research received no external funding.
Acknowledgments: This research was supported by grants from the Conselho Nacional de Desenvolvimento
Científico e Tecnológico (CNPq) and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (Capes).
Conflicts of Interest: The authors declare no conflict of interest.
References
1.
2.
3.
Nicolaou, k.C.; Theodorakis, E.A.; Rutjes, F.P.J.T.; Tiebes, J.; Sato, M.; Untersteller, E.; Xiao, X.-Y.; Total Synthesis
of Brevetoxin, B. 1. CDEFG Framework. J. Am. Chem. Soc. 1995, 117, 1171–1172. [CrossRef]
Vasconcellos, M.L.A.A.; Miranda, L.S.M. A reaç
ão de ciclização de Prins: uma estratégia eficiente para síntese
estereosseletiva de anéis tetraidropirânicos substituídos. Quím. Nova 2006, 29, 834–839. [CrossRef]
Umamatheswari, S.; Balaji, B.; Ramanathan, M.; Kabilan, S. Synthesis, antimicrobial evaluation and QSAR
studies of novel piperidin-4-yl-5-spiro-thiadiazoline derivatives. Eur J. of Med. Chem. 2011, 46, 1415–1429.
4.
Masuda, K.; Nishiwaki, H.; Akiyama, K.; Yamauchi, S.; Maruyama, M.; Sugahara, T.; Kishida, T. Antifungal
Activity of Morinol B Derivatives of Tetrahydropyran Sesquilignan. Bio. Biotec. Biochem. 2010, 74, 2071–2076.